Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods

Clinical Cancer Research

Volumn 8, Issue 1, 2002, Pages 171-179

  Lu, Ming Lan ^a   Charytonowicz, Elizabeth ^a   Cordon Cardo, Carlos ^a   Rabbani, Farhang ^a   Dalbagni, Guido ^a   Pohar, Kamal S ^a   Wikman, Friedrik ^b   Orntoft, Torben F ^b   Zhang, Zuofeng ^c   Yu, Guopei ^d  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; PROTEIN MDM2; PROTEIN P21; PROTEIN P53;

ARTICLE; BLADDER CANCER; CANCER SURVIVAL; DNA MICROARRAY; FOLLOW UP; FRAMESHIFT MUTATION; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; HUMAN; MAJOR CLINICAL STUDY; METHODOLOGY; MULTIVARIATE ANALYSIS; POINT MUTATION; PRIORITY JOURNAL; SAMPLING; SEQUENCE ANALYSIS; SINGLE STRAND CONFORMATION POLYMORPHISM;

CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; CYSTECTOMY; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; ENZYME INHIBITORS; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; GENOTYPE; HUMANS; IMMUNOENZYME TECHNIQUES; MUTATION; NEOPLASM PROTEINS; NEOPLASMS, GLANDULAR AND EPITHELIAL; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 0036157247     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. P53, the cellular gatekeeper for growth and division
2. P53 mutations in human cancer
3. Accumulation of nuclear p53 and tumor progression in bladder cancer
4. Detection of p53 mutations in superficial (T1) bladder carcinomas as a marker of disease progression
5. Evolutionary sequence comparisons using high-density oligonucleotide arrays
6. Cystic fibrosis mutation detection by hybridization to light-generated DNA probe arrays
7. Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array
8. Comparison of TP53 mutations identified by oligonucleotide microarray and conventional DNA sequence analysis
9. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53
10. Mdm2 promotes the rapid degradation of p53
11. The INK4a tumour suppressor gene product, p19/Arf, interacts with MDM2 and neutralizes MDM2’s inhibition of p53
12. The alternative product from the human CDK2A locus, p14ARF, participates in a regular feedback loop with p53 and MDM2
13. Functional and physical interactions of the ARF tumour suppressor with p 53 and MDM2
14. WAF1, a potential mediator of p53 tumor suppressor
15. High level of MDM2 is not correlated with the presence of wild-type p53 in human malignant mesothelioma cell lines
16. A new polymorphic site in intron 2 of TP53 characterizes LOH in human tumors by PCR-SSCP
17. Prognostic significance of transcription factor E2F-1 in bladder cancer: Genotypic and phenotypic characterization
18. Evaluation of the performance of a p53 sequencing microarray chip using 140 previously sequenced bladder tumor samples
19. Nonparametric estimation from incomplete observations
20. Regression modelslife tables
21. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations
22. How loops, B sheets, and helices help us to understand p53
23. The DNA-binding domain of p53 contains the four conserved regions and the major mutation "hot spots
24. P53: A transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer
25. Predictive value of cell cycle markers p53, mdm2, p21, and Ki-67 in superficial bladder tumor recurrence
26. Tumorigenic pathway in low-stage bladder cancer based on p53, mdm2 and p21 phenotypes
27. Tumor mapping of regional immunostaining for p21, p53, and mdm2 in locally advanced bladder carcinoma
28. p53, p21 and mdm2 expression vs. The response to radiotherapy in transitional cell carcinoma of bladder
29. The p53-mdm-2 autoregulatory feedback loop
30. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
31. Mapping of the p53 and mdm-2 interaction domains
32. Molecular abnormalities of MDM2 and p53 genes in adult soft tissue sarcomas
33. Mutant p53: Gain-of-function oncoproteins and wildtype p53 inactivators
34. Mutant p53 gain-offunction: Differential effects of different p53 mutants on resistance of cultured cells to chemotherapy
35. Effects of p51/p63 missense mutations on transcriptional activities of p53 downstream gene promoters
36. The transcriptional activities of p53 and its homologue p51/p63: Similarities and differences
37. Comparative analysis of p73 and p53 regulation and effector functions
38. Elevated and biallelic expression of p73 is associated with progression of human bladder cancer
39. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer
40. Biomarker study of primary nonmetastatic versus metastatic invasive bladder cancer
41. Analysis of p21WAF1/CIP1 in primary bladder tumors
42. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinase
43. Molecular genetic alterations in superficial and local human bladder cancer
44. Genetic alterations in bladder cancer
45. Molecular genetic alterations of chromosome 17 and p53 nuclear overexpression in human bladder cancer
46. p53 nuclear overexpression and disease progression in Ta bladder carcinoma